PHENOXYBENZAMINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Phenoxybenzamine Hydrochloride, and what generic alternatives are available?
Phenoxybenzamine Hydrochloride is a drug marketed by Amneal, Aurobindo Pharma, Hikma, Novitium Pharma, Par Pharm Inc, and Rising. and is included in six NDAs.
The generic ingredient in PHENOXYBENZAMINE HYDROCHLORIDE is phenoxybenzamine hydrochloride. There are seven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the phenoxybenzamine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Phenoxybenzamine Hydrochloride
A generic version of PHENOXYBENZAMINE HYDROCHLORIDE was approved as phenoxybenzamine hydrochloride by PAR PHARM INC on January 24th, 2017.
Summary for PHENOXYBENZAMINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 6 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 104 |
Clinical Trials: | 7 |
Patent Applications: | 637 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in PHENOXYBENZAMINE HYDROCHLORIDE? | PHENOXYBENZAMINE HYDROCHLORIDE excipients list |
DailyMed Link: | PHENOXYBENZAMINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for PHENOXYBENZAMINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Seoul National University Hospital | Phase 4 |
University of California, Los Angeles | Phase 3 |
Radboud University | Phase 4 |
Pharmacology for PHENOXYBENZAMINE HYDROCHLORIDE
Drug Class | alpha-Adrenergic Blocker |
Mechanism of Action | Adrenergic alpha-Antagonists |